Humans may be exposed to 2-aminoanthracen e (2-AA), a substituted polycyclic aromatic hydrocarbon, and a recognized mutagen and carcinogen, through oral and respiratory routes from contact with a variety of environmental sources. For the present study, we sought to evaluate hepatic damage and recovery in Fischer 344 rats following multiple IP injections of 5 mg of 2-AA. Rats were injected weekly for up to 5 weeks. Subgroups were then allowed to recover for 1, 5, or 9 weeks, and biochemical and pathologic changes were evaluated. We observed that weight gains were reduced relative to controls for all groups receiving ≥ 2 injections. Serum enzyme levels indicative of liver damage were evident and included alterations in serum aspartate aminotransferase, alkaline phosphatase, total protein, albumin, and globulin. These alterations usually returned to normal by 5 weeks following cessation of 2-AA administration. In contrast, histologic liver changes, including hepatocyte hypertrophy, biliary hyperplasia with oval cell proliferation, altered foci, nodular hyperplasia, and one hepatocellular adenoma became more severe with time. This experiment demonstrates patterns of hepatic damage and recovery in rats exposed to 2-AA.
Beland FA, Kadlubar FF (1985). Formation and persistence of arylamine DNA adducts in vivo. Environ Health Perspect62: 19—30.
2.
Bitsch A., Klohn PC, Hadjiolov N., Bergmann O., Neumann HG (1999). New insights into carcinogenesi s of the classical model arylamine 2-acetylaminofluorene. Cancer Lett143: 223—227.
3.
Boudreau MD, Baker DG, Taylor HW, Barker SA, Means JC (2000). Suppression of Arylamine Activation in the Fischer-344 Rat Following Ingestion of a Complex Mixture. Toxicol Pathol. Submitted for publication.
4.
Bruckner JV, MacKenzie WF, Muralidhara S., Luthra R., Kyle GM, Acosta D. (1986). Oral toxicity of carbon tetrachloride: Acute, subacute, and sub-chronic studies in rats. Fundam Appl Toxicol6: 16—34.
5.
. Dabeva MD, Alpini G, Hurston E, Shafritz DA (1993). Models for hepatic progenitor cell activation. Proc Soc Exp Biol Med 204: 242—252.
6.
Davis DP, Gomez MP, Barton SL, Montano RM, Burchiel SW (1991). Suppression of local gut-associated and splenic mitogen responsiveness of lymphoid cells following oral exposure of B6C3F1 mice to 7,12-dimethylbenz(a)anthracene. Fundam Appl Toxicol17: 429— 431.
7.
Feng Y., Fretland AJ, Rustan TD, Jiang W., Becker WK, Hein DW ( 1997). Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2'-dimethyl-4-aminobiphenyl . Toxicol Appl Pharmacol147: 56—62.
8.
Green MD, Tephly TR (1998). Glucuronidation of amine substrates by purifi ed and expressed UDP-glucuronosyltransferas e proteins. Drug Metab Dispo26: 860—867.
9.
Hlavica P., Golly I., Lehnerer M., Schulze J. (1997). Primary aromatic amines: Their N-oxidative bioactivation . Hum Exp Toxicol16: 441—448.
10.
King RS, Teitel CH, Shaddock JG, Casciano DA, Kadlubar FF (1999). Detoxifi cation of carcinogenic aromatic and heterocyclic amines by enzymatic reduction of the N-hydroxy derivative. Cancer Lett143: 167— 171.
11.
Kranendonk M., Mesquita P., Laires A., Vermeulen NP, Rueff J. (1998). Expression of human cytochrome P450 1A2 in Escherichia coli: A system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis13: 263—269.
12.
Moghaddam AP , Eggers JS, Calabrese EJ (1998). Evaluation of sex differences in tissue repair following acute carbon tetrachloride toxicity in male and female Sprague—Dawley rats. Toxicol130: 95—105.
13.
Neuman HG, Ambs S., Bitsch A. (1994). The role of nongenotoxic mechanisms in arylamine carcinogenesis. Environ Health Perspect102: 173—176.
14.
Ozawa S., Abu-Zeid M., Murayama N., Yamazoe Y., Kato R. ( 1990). Decrease in the metabolic activating capacities of arylamines in livers bearing hyperplastic nodules: Association with the selective changes in hepatic P-450 isozymes. Jpn J Cancer Res81: 247—252.
15.
Pinto JS, Dobson RL, Bentley JP (1970). Dermal collagen changes during 2-aminoanthracene carcinogenesi s in the rat. Cancer Res30: 1168—1173.
16.
Rainov NG, Dobberstein KU, Sena-Esteves M., Herrlinger U., Kramm CM, Philpot RM, Hilton J., Chiocca EA, Breakefi eld XO (1998). New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 9: 1261—1273.
17.
Rao PS, Mangipudy RS, Mehendale HM (1997). Tissue injury and repair as parallel and opposing responses to CCl4 hepatotoxicity: A novel dose-response. Toxicol118: 181—193.
18.
Roberts-ThomsonIC, Butler WJ,RyanP(1999). Meat, metabolic genotypes and risk for colorectal cancer. Eur J Cancer Prev8: 207—211.
19.
Skipper PL, Tannenbaum SR (1994). Molecular dosimetry of aromatic amines in human populations. Environ Health Perspect 102(suppl 6)17—21.
20.
Soni MG, Mangipudy RS, Mumtaz MM, Mehendale HM (1998). Tissue repair response as a function of dose during trichloroethylen ehepatotoxicity. Toxicol Sci42: 158—165.
21.
Terada M., Nagao M., Nakayasu M., Sakamoto H., Nakasato F., Sugimura T. (1986). Mutagenic activities of heterocyclic amines in Chinese hamsters lung cells in culture. Environ Health Perspect67:117—119.
22.
Vineis P. (1994). Epidemiology of cancer from exposure to arylamines. Environ Health Perspect 102(suppl 6)7—10.
23.
Vineis P., Pirastu R. (1997). Aromatic amines and cancer. Cancer Causes Control8: 346—355.
24.
Wang P-Y., Kaneko T., Tsukada H., Nakano M., Nakajima T., Sato A. ( 1997). Time courses of hepatic injuries induced by chloroform and by carbon tetrachloride: Comparison of biochemical and histopathological changes. Arch Toxicol71: 638—645.
25.
Windmill KF , McKinnon RA, Zhu X., Gaedigk A., Grant DM, McManus ME (1997). The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: Functional and localization studies. Mutat Res376: 153—160.
26.
Wise RW, Zenser TV, Kadlubar FF, Davis BB (1984). Metabolic activation of carcinogenic aromatic amines by dog bladder and kidney prostaglandin H synthase. Cancer Res44: 1893—1897.
